© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Guillermo Garcia-Manero, MD
Articles
Guillermo Garcia-Manero, MD, on Eprenetapopt-Azacytidine Combo in TP53+ MDS
June 18, 2020
ByGuillermo Garcia-Manero, MDThe MD Anderson expert discussed the phase 3 trial – designed to evaluate frontline eprenetapopt in combination with azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) – that recently completed full enrollment.
Myelodysplastic Syndromes
June 01, 2016
ByGuillermo Montalban-Bravo, MD|Guillermo Garcia-Manero, MD|Alan List, MD|Hagop M. Kantarjian, MD|Jorge E. Cortes, MDMyelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis.
Cancer Management Chapter 32: Myelodysplastic syndromes
March 13, 2010
ByGuillermo Garcia-Manero, MD|Alan List, MD|Hagop M. Kantarjian, MD|Jorge E. Cortes, MDMyelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis. The overall clinical phenotype is peripheral cytopenias in the setting of a normocellular or hypercellular bone marrow and an increased risk for transformation to acute leukemia.
Management of Myelodysplastic Syndromes: Just the Beginning
November 01, 2008
ByHawk Kim, MD|Guillermo Garcia-Manero, MDDrs. Scott and Estey provide an excellent, concise review of current diagnostic and therapeutic approaches for patients with myelodysplastic syndromes (MDS). Both physicians are recognized world leaders in this area.